Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 2011;29(15):2066–2070. DOI:10.1200/JCO.2010.32.6181.
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–346. DOI:10.1093/jnci/dji055.
   PubMed Web of Science ®Google Scholar
• Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309(5967):418–425. DOI:10.1038/309418a0.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Garrett TP, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002;110(6):763–773. DOI:10.1016/S0092-8674(02)00940-6.
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211–225.
   PubMed Web of Science ®Google Scholar
• Ward WH, Cook PN, Slater AM, et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol. 1994;48(4):659–666.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al., Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 378(2): 113–125. 2018. 10.1056/NEJMoa1713137.
   PubMed Web of Science ®Google Scholar
• Bria E, Milella M, Cuppone F, et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol. 2011;22(10):2277–2285. DOI:10.1093/annonc/mdq742.
   PubMed Web of Science ®Google Scholar
• Passaro A, Jänne PA, Mok T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer. Nature Cancer. 2021;2(4):377–391. doi:10.1038/s43018-021-00195-8.
   PubMedGoogle Scholar
• Schmid S, Li JJN, Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer. 2020;147:123–129.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Xu CR, Cheng Y, et al., Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study. Cancer Cell. 39(9): 1279–1291.e1273. 2021. 10.1016/j.ccell.2021.07.005.
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Alfieri R, La Monica S, et al. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives. Crit Rev Oncol Hematol. 2020;146:102820.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181.
   PubMed Web of Science ®Google Scholar
• Dokala A, Thakur SS. Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery. Oncogene. 2017;36(17):2337–2344.
   PubMed Web of Science ®Google Scholar
• Prabhakar CN. Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(2):110–118.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361(10): 947–957. 2009. 10.1056/NEJMoa0810699.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640. DOI:10.1056/NEJMoa1612674.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–2874. DOI:10.1200/JCO.2010.33.4235.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–1889. DOI:10.1093/annonc/mdv270.
   PubMed Web of Science ®Google Scholar
• Lee CK, Davies L, Wu YL, et al. Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. J Natl Cancer Inst. 2017;109(6). DOI:10.1093/jnci/djw279.
   Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer. 2012;13(2):107–114.
   PubMed Web of Science ®Google Scholar
• Zhou JY, Liu SY, Wu YL. Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. Expert Opin Drug Saf. 2020;19(5):589–599.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of Afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334. DOI:10.1200/JCO.2012.44.2806.
   PubMed Web of Science ®Google Scholar
• Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–151. DOI:10.1016/S1470-2045(14)71173-8.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28(2):270–277. DOI:10.1093/annonc/mdw611.
   PubMed Web of Science ®Google Scholar
• Yang JC, Sequist LV, Geater SL, et al. Clinical activity of Afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–838. DOI:10.1016/S1470-2045(15)00026-1.
   PubMed Web of Science ®Google Scholar
• Miura S, Yamanaka T, Kato T, et al. Treatment rationale and design of a phase iii study of afatinib or chemotherapy in patients with non-small-cell lung cancer harboring sensitizing uncommon epidermal growth factor receptor mutations (ACHILLES/TORG1834). Clin Lung Cancer. 2020;21(6):e592–e596. DOI:10.1016/j.cllc.2020.05.011.
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–1466. DOI:10.1016/S1470-2045(17)30608-3.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Mok TS, Zhou X, et al. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer. 2021;154:176–185.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al., Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382(1): 41–50. 2020. 10.1056/NEJMoa1913662.
   PubMed Web of Science ®Google Scholar
• Park S, Lee MH, Seong M, et al. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol. 2020;31(10):1397–1404. DOI:10.1016/j.annonc.2020.06.017.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Wakuda K, Fukuda M, et al. A phase II study of osimertinib for radiotherapy-naive central nervous system metastasis From NSCLC: results for the T790M Cohort of the OCEAN study (LOGIK1603/WJOG9116L). J Thorac Oncol. 2021;16(12):2121–2132. DOI:10.1016/j.jtho.2021.07.026.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Murakami H, Yang PC, et al. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016;34(27):3258–3266. DOI:10.1200/JCO.2016.66.9218.
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38(2):115–123. DOI:10.1200/JCO.19.01488.
   PubMed Web of Science ®Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38(2):124–136. DOI:10.1200/JCO.19.01154.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Asahina H, Kishimoto J, et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial. Eur J Cancer. 2021;149:14–22.
   PubMed Web of Science ®Google Scholar
• Planchard D, Feng PH, Karaseva N, et al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open. 2021;6(5):100271. DOI:10.1016/j.esmoop.2021.100271.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377(9780):1846–1854. DOI:10.1016/S0140-6736(11)60545-X.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Fukuhara T, Saito H, et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2021;10(1):72–82. DOI:10.1016/S2213-2600(21)00166-1.
   PubMedGoogle Scholar
• Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655–1669. DOI:10.1016/S1470-2045(19)30634-5.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13(1):e23–31.
   PubMed Web of Science ®Google Scholar
• Meador CB, Sequist LV, Piotrowska Z. Targeting EGFR Exon 20 insertions in non-small cell lung cancer: recent advances and clinical updates. Cancer Discov. 2021;11(9):2145–2157.
   PubMed Web of Science ®Google Scholar
• Park K, Haura EB, Leighl NB, et al., Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 39(30): 3391–3402. 2021. 10.1200/JCO.21.00662.
   PubMed Web of Science ®Google Scholar
• Riely GJ, Neal JW, Camidge DR, et al. Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR Exon 20 insertion mutations from a phase I/II trial. Cancer Discov. 2021;11(7):1688–1699. DOI:10.1158/2159-8290.CD-20-1598.
   PubMed Web of Science ®Google Scholar
• Zhou C, Ramalingam S, Li B, et al. OA04.03 mobocertinib in NSCLC with EGFR exon 20 insertions: results from EXCLAIM and pooled platinum-pretreated patient populations. J Thorac Oncol. 2021;16(3, Supplement):S108. DOI:10.1016/j.jtho.2021.01.283.
   Web of Science ®Google Scholar
• Goss GD, O’Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013;31(27):3320–3326. DOI:10.1200/JCO.2013.51.1816.
   PubMed Web of Science ®Google Scholar
• Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33(34):4007–4014. DOI:10.1200/JCO.2015.61.8918.
   PubMed Web of Science ®Google Scholar
• Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6(11):863–873. DOI:10.1016/S2213-2600(18)30277-7.
   PubMed Web of Science ®Google Scholar
• He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021;9(9):1021–1029. DOI:10.1016/S2213-2600(21)00134-X.
   PubMed Web of Science ®Google Scholar
• Tada H, Mitsudomi T, Yamanaka T, et al., Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): a randomized phase 3 trial. J clin oncol. 39(15_suppl): 8501. 2021. 10.1200/JCO.2021.39.15_suppl.8501.
   Web of Science ®Google Scholar
• Pennell NA, Neal JW, Chaft JE, et al. SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol. 2019;37(2):97–104. DOI:10.1200/JCO.18.00131.
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Wang Q, Mao WM, et al., Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 19(1): 139–148. 2018. 10.1016/S1470-2045(17)30729-5.
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021;39(7):713–722. DOI:10.1200/JCO.20.01820.
   PubMed Web of Science ®Google Scholar
• Lin C, Hu F, Chu H, et al. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: a meta-analysis. Thorac Cancer. 2021;12(7):1084–1095.
   PubMed Web of Science ®Google Scholar
• Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–1723. DOI:10.1056/NEJMoa2027071.
   PubMed Web of Science ®Google Scholar
• Lu S, Dong X, Jian H, et al. Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm). J Clin oncol. 2021;39(15_suppl):9013. DOI:10.1200/JCO.2021.39.15_suppl.9013.
   Google Scholar
• Chen RL, Sun LL, Cao Y, et al. Adjuvant EGFR-TKIs for patients with resected EGFR-mutant non-small cell lung cancer: a meta-analysis of 1,283 patients. Front Oncol. 2021;11:629394.
   PubMed Web of Science ®Google Scholar
• Yun J, Hong MH, Kim SY, et al. YH25448, an Irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer. Clin Cancer Res. 2019;25(8):2575–2587.
   PubMed Web of Science ®Google Scholar
• S-W K, Ahn M-J, Han J-Y, et al. Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: data from a phase I/II study. J Clin oncol. 2020;38(15):9571.
   Web of Science ®Google Scholar
• Bauml J, Cho BC, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. J Clin oncol. 2021;39(15_suppl):9006. DOI:10.1200/JCO.2021.39.15_suppl.9006.
   Web of Science ®Google Scholar
• Lu S, Zhang Y, Zhang G, et al. Abstract CT170: d-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156). Cancer Res. 2021;81(13 Supplement):CT170–CT170. CT170. DOI:10.1158/1538-7445.AM2021-CT170.
   Web of Science ®Google Scholar
• Shi Y, Fang J, Shu Y, et al. 476O - A phase I study to evaluate safety and efficacy of BPI-7711 in EGFRm+/T790M+ advanced or recurrent NSCLC patients. Ann Oncol. 2019;30:ix158–ix159.
   Google Scholar
• Shi Y, Hu X, Zhang S, et al. Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: a phase IIb multicenter single-arm study. J Clin oncol. 2020;38(15_suppl):9602. DOI:10.1200/JCO.2020.38.15_suppl.9602.
   Google Scholar
• Tan DS-W, Leighl NB, Yang JC-H, et al. Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): updated phase II results. J Clin oncol. 2020;38(15_suppl):9574. DOI:10.1200/JCO.2020.38.15_suppl.9574.
   Google Scholar
• Lim SM, Park CW, Zhang Z, et al. Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC). Cancer Res. 2021;81(13 Supplement):1467.
   Web of Science ®Google Scholar
• Lim SM, Kim, Jung, et al. A phase 1/2, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy. Ann Oncol. 2021;32(suppl_5):S949–S1039. DOI:10.1016/j.annonc.2021.08.1966.
   Google Scholar
• Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254–e262.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Koyama K, Kamai Y, et al. A novel HER3-targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clin Cancer Res. 2019;25(23):7151–7161. DOI:10.1158/1078-0432.CCR-19-1745.
   PubMed Web of Science ®Google Scholar
• Janne PA, Baik C, Su WC, et al., Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR Inhibitor–resistant, EGFR -mutated non–small cell lung cancer. Cancer Discov. 12(1): 74–89. 2021. 10.1158/2159-8290.CD-21-0715.
   PubMed Web of Science ®Google Scholar
• Yun J, Lee SH, Kim SY, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov. 2020;10(8):1194–1209. DOI:10.1158/2159-8290.CD-20-0116.
   PubMed Web of Science ®Google Scholar
• Park K-S, John T, Kim S-W, et al. Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). J Clin oncol. 2020;38(15_suppl):9512. DOI:10.1200/JCO.2020.38.15_suppl.9512.
   Web of Science ®Google Scholar
• Syed YY. Amivantamab: first approval. Drugs. 2021;81(11):1349–1353.
   PubMed Web of Science ®Google Scholar
• Gonzalvez F, Vincent S, Baker TE, et al. Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer. Cancer Discov. 2021;11(7):1672–1687. DOI:10.1158/2159-8290.CD-20-1683.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Zhou C, Kim T, et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. J Clin oncol. 2021;39(15_suppl):9014. DOI:10.1200/JCO.2021.39.15_suppl.9014.
   Web of Science ®Google Scholar
• Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(5):638–646. DOI:10.1038/s41591-018-0007-9.
   PubMed Web of Science ®Google Scholar
• Cornelissen R, Garassino MC, Le X, et al. MA11.04 updated efficacy, safety and dosing management of poziotinib in previously treated EGFR and HER2 exon 20 NSCLC patients. J Thorac Oncol. 2021;16(3):S173–S174. DOI:10.1016/j.jtho.2021.01.249.
   Web of Science ®Google Scholar
• Le X, Garassino M, Cornelissen R, et al. CNS activity of poziotinib in NSCLC with exon 20 insertion mutations. J Clin oncol. 2021;39(15_suppl):9093. DOI:10.1200/JCO.2021.39.15_suppl.9093.
   Web of Science ®Google Scholar
• Yang JC-H, Wang M, Mitchell P, et al. Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. J Clin oncol. 2021;39(15_suppl):9008. DOI:10.1200/JCO.2021.39.15_suppl.9008.
   Web of Science ®Google Scholar
• Estrada-Bernal A, Le AT, Doak AE, et al. Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes. Clin Cancer Res. 2021;27(5):1463–1475. DOI:10.1158/1078-0432.CCR-20-3555.
   PubMed Web of Science ®Google Scholar
• Hasako S, Terasaka M, Abe N, et al. TAS6417, A novel EGFR inhibitor targeting exon 20 insertion mutations. Mol Cancer Ther. 2018;17(8):1648–1658. DOI:10.1158/1535-7163.MCT-17-1206.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Yu HA, Yang JC-H, et al. Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR exon 20 insertion mutations (Ins20). J Clin oncol. 2021;39(15_suppl):9077. DOI:10.1200/JCO.2021.39.15_suppl.9077.
   Web of Science ®Google Scholar
• Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958–3965. DOI:10.1158/0008-5472.CAN-03-2868.
   PubMed Web of Science ®Google Scholar
• Boni V, Dooms C, Haley B, et al. OA04.06 Neratinib in Pretreated EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): initial findings from the SUMMIT basket trial. J Thorac Oncol. 2021;16(3, Supplement):S110. DOI:10.1016/j.jtho.2021.01.286.
   Web of Science ®Google Scholar
• Yang Z, Guo Q, Wang Y, et al. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016;8(368):368ra172. DOI:10.1126/scitranslmed.aag0976.
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Kim DW, Cho BC, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017;5(11):891–902. DOI:10.1016/S2213-2600(17)30378-8.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. DOI:10.1126/scitranslmed.3002003.
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. DOI:10.1158/1078-0432.CCR-12-2246.
   PubMed Web of Science ®Google Scholar
• Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784–1793. DOI:10.1016/j.jtho.2019.06.002.
   PubMed Web of Science ®Google Scholar
• Wang W, Xu C, Chen H, et al. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: a multicenter retrospective study. Lung Cancer. 2021;155:20–27.
   PubMed Web of Science ®Google Scholar
• Wang S, Xie T, Hao X, et al. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. Thorac Cancer. 2021;12(19):2585–2593. DOI:10.1111/1759-7714.14144.
   PubMed Web of Science ®Google Scholar
• Kim Y, Lee B, Shim JH, et al. Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC. J Thorac Oncol. 2019;14(2):193–202. DOI:10.1016/j.jtho.2018.10.150.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer. J Thorac Oncol. 2021;16(10):1647–1662. DOI:10.1016/j.jtho.2021.06.017.
   PubMed Web of Science ®Google Scholar
• Dong S, Wang Z, Zhou Q, et al. P49.01 drug holiday based on minimal residual disease status after local therapy following EGFR-TKI treatment for patients with advanced NSCLC. J Thorac Oncol. 2021;16(10):S1113–S1114. DOI:10.1016/j.jtho.2021.08.529.
   Web of Science ®Google Scholar
• Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent. J Clin Oncol. 2022;40(6):567–575.
   PubMed Web of Science ®Google Scholar
• Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394–1403. DOI:10.1158/2159-8290.CD-17-0716.
   PubMed Web of Science ®Google Scholar
• Mok TS, Cheng Y, Zhou X, et al. Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. Drugs. 2021;81(2):257–266. DOI:10.1007/s40265-020-01441-6.
   PubMed Web of Science ®Google Scholar
• Passaro A, Mok T, Peters S, et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions. EGFR Mutations. J Thorac Oncol. 2021;16(5):764–773. doi:10.1016/j.jtho.2020.12.002.
   PubMed Web of Science ®Google Scholar
• Yang JC, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol. 2020;15(5):803–815. DOI:10.1016/j.jtho.2019.12.126.
   PubMed Web of Science ®Google Scholar
• Choudhury NJ, Schoenfeld AJ, Flynn J, et al. Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions. Clin Cancer Res. 2021;27(10):2920–2927. DOI:10.1158/1078-0432.CCR-20-4650.
   PubMed Web of Science ®Google Scholar
• Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4(1):5.
   PubMedGoogle Scholar
• Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179–184. DOI:10.1097/JTO.0b013e3182779d18.
   PubMed Web of Science ®Google Scholar
• Lee CK, Wu YL, Ding PN, et al. Impact of specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J Clin Oncol. 2015;33(17):1958–1965. DOI:10.1200/JCO.2014.58.1736.
   PubMed Web of Science ®Google Scholar
• Hanibuchi M, Kim SJ, Fidler IJ, et al. The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives. J Med Invest. 2014;61(3–4):241–253.
   PubMedGoogle Scholar
• Waqar SN, Samson PP, Robinson CG, et al. Non-small-cell lung cancer with brain metastasis at presentation. Clin Lung Cancer. 2018;19(4):e373–e379. DOI:10.1016/j.cllc.2018.01.007.
   PubMed Web of Science ®Google Scholar
• Erickson AW, Brastianos PK, Das S. Assessment of effectiveness and safety of osimertinib for patients with intracranial metastatic disease: a systematic review and meta-analysis. JAMA Network Open. 2020;3(3):e201617.
   PubMed Web of Science ®Google Scholar
• Wu YL, Ahn MJ, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36(26):2702–2709. DOI:10.1200/JCO.2018.77.9363.
   PubMed Web of Science ®Google Scholar
• Xing L, Pan Y, Shi Y, et al. Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases: the APOLLO study. Clin Cancer Res. 2020;26(23):6168–6175. DOI:10.1158/1078-0432.CCR-20-2081.
   PubMed Web of Science ®Google Scholar
• Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10(1):156–163. DOI:10.1097/JTO.0000000000000380.
   PubMed Web of Science ®Google Scholar
• Arbour KC, Kris MG, Riely GJ, et al. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer. 2018;124(1):105–109. DOI:10.1002/cncr.30990.
   PubMed Web of Science ®Google Scholar
• Peng W, Pu X, Jiang M, et al. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: a brief report. Lung Cancer. 2021;152:66–70.
   PubMed Web of Science ®Google Scholar
• Palmieri D, Chambers AF, Felding-Habermann B, et al. The biology of metastasis to a sanctuary site. Clin Cancer Res. 2007;13(6):1656–1662.
   PubMed Web of Science ®Google Scholar